Regeneron Canada Says Libtayo Receives Health Canada Approval For Treatment Of A Type Of Carcinoma
REGN•Health Canada approves Libtayo for adjuvant use
- Regeneron Canada: Libtayo receives Health Canada approval for adjuvant treatment of high-risk cutaneous squamous cell carcinoma
Source text: ID:nCNWj2k0ca
Further company coverage: REGN.O
